Steady Development of Novel Treatments and Replacement Therapies to Boost Hemophilia Market

Published Date : May 02, 2017

Albany, New York, May 2, 2017: has announced the addition of a report titled “Global Hemophilia Market: Industry Analysis & Outlook (2017-2021)” to its offering. The comprehensive report on the global hemophilia market provides insight into the major drivers and restraints, current trends and emerging opportunities, market share and size of various segments, and competitive landscape. The research report covers recent R&D activities related to diagnostics and therapeutics and highlights current treatment options and key initiatives of leading pharmaceutical companies developing gene therapies. Prominent government programs supporting these initiatives are also elaborated in the report.

The research study evaluates the healthcare expenditure in major countries and prominent treatment options in hemophilia C, hemophilia B, hemophilia A, and hemophilia with inhibitors. The study takes a close look at various marketed therapies and emerging promising pipeline products and assesses their impact on the strategic dynamics in major regions. The launch of novel products and gene therapies is expected to significantly alter the competitive dynamics of the global hemophilia market.

Growing focus on prophylactic treatment and the soaring need for diagnosis of the diseases in various regions are the key factors propelling the hemophilia market. The growing market for FVIII or anti-hemophilic factor (AHF) and spiraling healthcare expenditure in developed regions are expected to fuel the growth of the market. The launch of subcutaneous dosing for the treatment of hemophilia A and B and the development of novel therapies are anticipated to boost the market.

For Sample Copy, click here:

Increasing demand for recombinant versions of factor VIII and IX drugs is expected to positively impact the market in the coming years. Recent development of extended half-life factor VIII and factor IX concentrates has significantly reduced annual bleeding rates in clinical trials. This is an encouraging step in the development of novel therapies. Leading pharmaceutical players are expected to launch their novel gene therapies for treating all types of hemophilia by 2030. This is expected to significantly alter the market dynamics across the world.

However, the high cost of treatments and reluctance among patients to switch to novel therapies, especially in underdeveloped regions, are likely to hinder the market to an extent. Nevertheless, the growing popularity of gene therapies in disease diagnosis is expected to unlock exciting opportunities for market players over the forecast period. Furthermore, the competitive pricing strategies adopted by several players are likely to result in a decline in prices of hemophilia treatments in the coming years. In addition, the presence of financial assistance programs by large healthcare providers is expected to accentuate the growth of the hemophilia market.

Leading players in the global hemophilia market are intensively focused on developing novel gene therapies and making substantial R&D investments in clinical studies for their prominent pipeline products. This is expected to expedite the commercialization of major therapies, opening lucrative avenues for players in the hemophilia market. The market is intensely competitive and with few large players. Leading companies operating in this market include Novo Nordisk, Shire Plc., Bayer Group, and Pfizer Inc.      

To order report Call Toll Free: 866-997-4948 or send an email on